Stock DNA
Pharmaceuticals & Biotechnology
SEK 164 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.01
-444.23%
49.68
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Mar 2025)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
208.39%
0%
208.39%
6 Months
252.8%
0%
252.8%
1 Year
96.87%
0%
96.87%
2 Years
7503.45%
0%
7503.45%
3 Years
-79.05%
0%
-79.05%
4 Years
-94.6%
0%
-94.6%
5 Years
-98.18%
0%
-98.18%
MyFirstApp Sweden AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.59%
EBIT Growth (5y)
11.61%
EBIT to Interest (avg)
-6.73
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
0.33
Tax Ratio
2.10%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
15.89%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
38.83
EV to EBIT
-54.62
EV to EBITDA
-128.03
EV to Capital Employed
39.18
EV to Sales
91.54
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-71.73%
ROE (Latest)
-444.23%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2.50
2.10
19.05%
Operating Profit (PBDIT) excl Other Income
-0.40
-2.00
80.00%
Interest
1.20
0.10
1,100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-11.70
-4.20
-178.57%
Operating Profit Margin (Excl OI)
-1,724.70%
-1,826.00%
10.13%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 19.05% vs 425.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -178.57% vs -4,300.00% in Dec 2023
About MyFirstApp Sweden AB 
MyFirstApp Sweden AB
Pharmaceuticals & Biotechnology
ObsteCare AB is a Sweden-based provider of solutions within area of childbirth care. The Company is a developer of Amniotic Fluid Lactate (AFL) method, which aims to measure lactic acid content in the fetal water. Samples of amniotic fluid are collected and analyzed for the concentration of lactate. The lactate level is automatically presented in the partogram. By combining the result with the development of cervix dilatation a thorough understanding of the delivery status is obtained. The fluid is collected with a standard syringe. The fluid is delivered into the single use measuring probe on the measuring unit and the measurement starts automatically. The method is used by clinics primarily in the Nordic countries, the United Kingdom and the Baltic States.
Company Coordinates 
Company Details
Fogdevreten 2 , SOLNA None : 171 65
Registrar Details






